First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells.

Trial Profile

First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2016

At a glance

  • Drugs AV 0113 (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms GBM-Vax
  • Sponsors Activartis Biotech
  • Most Recent Events

    • 17 Oct 2015 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database.
    • 30 May 2014 Interim results on overall survival presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 10 Apr 2013 Interim results presented at the 104th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top